Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Cybin Inc. < Previous 1 2 3 4 5 6 Next > Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs January 04, 2024 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program December 06, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results December 05, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses November 30, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City November 20, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023 November 16, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting November 15, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Reports Second Quarter Financial Results and Recent Business Highlights November 14, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders November 14, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces up to US$64 Million Offering of Units November 10, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate at the 2023 Milken Institute Future of Health Summit November 03, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline November 01, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose October 31, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs October 26, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program October 25, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics October 23, 2023 From Cybin Inc. Via Business Wire Tickers CYBN DMTTF TSX-V:DMT Small Pharma Obtains Final Order Approving Arrangement October 17, 2023 From Cybin Inc. Via Business Wire Tickers CYBN DMTTF TSX-V:DMT Cybin Announces Results of Annual and Special Meeting of Shareholders October 12, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit October 06, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit October 04, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder October 03, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder September 27, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial September 26, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Participate in the Cantor Global Healthcare Conference September 25, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Date of Annual and Special Meeting of Shareholders September 21, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder September 21, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines September 05, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin to Acquire Small Pharma Inc. August 28, 2023 From Cybin Inc. Via Business Wire Tickers CYBN DMTTF TSX-V:DMT Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million August 23, 2023 From Cybin Inc. Via Business Wire Tickers CYBN Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial August 17, 2023 From Cybin Inc. Via Business Wire Tickers CYBN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.